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ABSTRACT
Objective: The Panel on Cost-Effectiveness in Health and
Medicine recommended the compilation of a catalog of
health state utility weights for use in cost-utility analyses
(CUAs), and has given methodological recommendations.
This study presents an update, through 2001, to our current
registry of utility weights (available at http://www.tufts-
nemc.org/cearegistry; previously at http://www.hsph.
harvard.edu/cearegistry), and documents recent changes in
methods used for utility weight elicitation.
Methods: We searched the English-language medical litera-
ture for original CUAs reporting outcomes as cost per qual-
ity-adjusted life-year (QALY). Two trained readers
independently audited each article, abstracting data on the
health state descriptions, corresponding utility weights,
methods of elicitation, and sources of the estimates. The util-
ity elicitation methods from 1998 to 2001 were compared
with the methods used to obtain utilities before 1998.
Results: We identified 306 CUAs published after 1998,
reporting 1210 separate health-related utility estimates,
bringing the total in our catalog to 2159 weights. Most fre-
quently, health states pertained to the circulatory system and
oncology. Methods varied substantially: 36% of authors
used direct elicitation (standard gamble, time trade-off or
rating scale), 23% used generic health status instruments
(EQ-5D, Health Utilities Index, etc.), and 25% estimated
weights based on clinical judgment. Community preferences
were used in 27% of the values. Compared with pre-1998,
utilities published from 1998 to 2001 were more likely to be
elicited using a generic instrument, more likely elicited from
community samples, and less likely derived from expert opin-
ion, with no formally employed methodology.
Conclusions: Increasingly, analysts conducting CUAs are
using generic, preference-weighted instruments, and relying
on community-based preferences. Our catalog of utility
weights provides a useful reference tool for producers and
consumers of CUAs, but also highlights the continued need
for improvement in methods and transparency.
Keywords: cost-effectiveness analysis, cost-utility analysis,
health utility, quality-adjusted life-year.
Introduction
Cost-utility analysis (CUA) is a type of cost-effective-
ness analysis in which health effects are measured in
terms of quality-adjusted life-years (QALYs) gained or
other preference-based outcome measures, allowing
comparison of diverse interventions and health-care
programs. Many experts and consensus groups have
recommended CUA as the gold standard for conduct-
ing economic evaluations [1–5].
QALYs are calculated by weighting each time inter-
val in a given state by its “utility”—a value between 0
and 1 that reflects the individual’s preference for that
health state relative to perfect health (weighted 1) and
death (weighted 0). Once the utility weights are
obtained for each state, they are multiplied by the time
spent in the state and the products are summed to
obtain the total number of QALYs (e.g., living 3 years
with a utility value of 0.8 will produce 2.4 QALYs) [5].
Authors sometimes use the terms “utility,” “value,”
“preference score,” and “quality of life weight” inter-
changeably. For the remainder of this article, we use
“utility” to encompass all of these terms.
Utility weights can be provided by direct measure-
ment in patients, clinicians or the general population
using preference-based techniques like the standard
gamble and the time trade-off. Alternatively, utilities
can be assigned indirectly by using a utility-weighted
health status index (i.e., EuroQoL [6], Health Utility
Index [7,8], Quality of Well-Being Scale [9]). In the
second case, health status is assessed and then the util-
ity score is calculated by applying preexisting weights
to the health status domains. Whether preference- or
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nonpreference-based methods are used, consensuses
groups have recommended that utility weights be
derived from the community using as large a sample
size as possible [1–5].
Although primary data collection of utility weights
may be preferable, this may not be feasible because of
the time or expense involved. One alternative is to use
estimates from prior research. In 1996, the US Panel
on Cost-Effectiveness in Health and Medicine (the
Panel) recommended that researchers should assemble
a catalog of utility weights that could provide a con-
venient reference tool for use by researchers and poli-
cymakers [5]. Researchers have responded by mapping
preference data to health status instruments [10,11],
using community responses to assess the health-related
quality-of  life  for  a  wide  variety  of  conditions  [12],
and developing catalogs of published utility weights
[13,14]. The goal is a publicly available catalog of
well-described health states and utility values to allow
users to obtain relevant utilities for their analyses.
Recently, researchers at the Harvard School of
Public Health and Tufts-New England Medical Center
developed a comprehensive registry of CUAs, contain-
ing detailed information on studies published in the
health and medical literature from 1976 to 2001 [15].
We previously examined and cataloged all utility
weights for health states in CUAs published through
1997 [13]. The objectives of the current study were to
update this catalog to include utilities published from
1998 to 2001, and to document recent changes in the
methods used for utility elicitation. We hypothesized
that after 1998, because of the recommendations of
the Panel, we would begin to see improved utility
elicitation methods and more transparent reporting of
these methods in the literature.
Methods
This study was performed as part of a larger study
reviewing all original CUAs in medicine [15–18].
Study details including information on the cost-
utility ratios [17], utility values [13], and reporting
practices [15,16] are described elsewhere in detail,
and a comprehensive registry of these CUAs is avail-
able at (http://www.tufts-nemc.org/cearegistry). For
this larger study, a Medline search of the English-
language literature published between 1976 and
2001 was performed using the medical subject
headings and/or text keywords “quality-adjusted,”
“QALY,” and “cost-utility.” Our search findings
were validated to those of the Health Economic
Evaluation Database (HEED) used by the British
National Health Service [19].
As an update to this larger registry of CUAs and to
our previously published catalog of utility weights
reported in the CUAs published between 1976 and
1997 [13] we systematically reviewed the CUAs pub-
lished from 1998 to 2001 for data on all utilities used
or reported in these studies. Two trained readers inde-
pendently abstracted data on each health state
description, the corresponding utility point estimate
and ranges, the methods of elicitation, and the sources
of the estimates. Readers met to reach consensus on
the results and a third reviewer adjudicated any dis-
crepancies. The first author (C.B.) then reviewed all
articles to determine if original references needed to be
consulted for clarification or supplementation of the
utility data. Whenever possible, original references
were consulted if utility weights were obtained from
previous studies. When health state descriptions or
utility estimates were not completely presented in the
article or in another obtainable reference, they were
excluded from the catalog and this study. When the
same original source of utilities was referenced and
used by more than one CUA, it was included only
once. When defining the health state, we attempted, as
much as possible, to record and report the terms used
by the original authors. Nevertheless, we also
recorded any relevant contextual information and
occasionally amended the language to improve the
clarity of the description.
All health state descriptions were mapped by
trained physicians (C.B. and A.R.) into disease cate-
gories corresponding to several International Classi-
fication of Diseases 9th Revision (ICD-9) codes [20].
The utility catalog (http://www.tufts-nemc.org/
careregistry) was then updated to include the 1998–
2001 data within each appropriate disease category.
It is important to note one data collection change
made in the current study (1998–2001) compared with
our earlier catalog of utilities (1976–1997). Specifi-
cally, we record and report on utilities and their sta-
tistical ranges (i.e., standard deviation) in the current
study, although our earlier catalog reports on any men-
tioned range of values around utilities regardless of
statistical relationships. As a result, fewer ranges
around the utility estimates are presented in this 1998–
2001 update.
Analyses
The complete catalog of utility weights from 1976 to
2001 was then analyzed to determine the distribu-
tion of: 1) the utilities across disease categories; 2)
the utility elicitation techniques used; 3) the differ-
ent source populations (i.e., patients, general popula-
tion) used; and 4) the range of estimates provided
for similar health states. To explore the impact of
the Panel’s recommendations, we examined how
preference elicitation methods used in 1998–2001
differed from those used before 1998. For compari-
sons between the two time periods, proportions were
compared using the chi-square test. A P-value less
than 0.05 on two-tailed tests was considered statisti-
cally significant.
Utility Weights from CUAs 215
Results
From 1976 to 2001, 533 CUAs reported 2159 sepa-
rate utilities, with 306 of the CUAs and 1210 of the
utilities published after 1998. The majority of utilities
for health states pertained to cardiovascular disease
(19.9%) and oncology (19.1%). Many disease catego-
ries, such as mental health, blood disorders and the
genitourinary system had few published utility values
(Fig. 1).
In general, the health state utilities were clustered at
higher values (Fig. 2). Four hundred and seventy-seven
health states (22.2%) were valued above 0.9, whereas
72 (6%) were valued lower than 0.3. Six health states
were valued below zero, suggesting that respondents
considered these health states to be worse than death.
Health state utilities were obtained using several
different methods (Table 1). Five hundred seventy-four
(26.6%) health state descriptions were valued by direct
time trade-off or standard gamble techniques, and 194
(9.0%) by rating scale techniques. For the 499
(23.1%) weights estimated using a generic health state
classification instrument, the most commonly used
instrument was the EQ-5D (EuroQol) in 161 health
states (7.5%). The Quality of Well-Being (5.0%) and
the Health Utilities Index (2.5%) were also commonly
used.
Utilities were obtained from several different source
populations. Five hundred thirty-five (24.8%) utilities
were derived from clinician or author input without
any formal methodology employed. A total of 590
(27.3%) health states were valued using community-
based weights. This included both the cases where the
authors directly elicited weights from members of the
community, and those using generic instruments that
relied on previously derived community weights. Five
hundred thirty-six of the health state descriptions
(24.8%) were valued by patients. The frequency with
which authors followed the Panel recommendation, to
elicit community weights using a generic instrument, is
shown in Figure 3, stratified by disease category.
Different studies often reported different utility
weights for the same health state. For example, since
1998, nine weights for myocardial infarction with sim-
ilar health state descriptions have reported point esti-
mates ranging from 0.58 to 0.93. In other disease
Figure 1 Number of health state descriptions
and utility weights by disease category from
published cost-utility analyses 1976–2001.
(Total = 2159).
Figure 2 Distribution of utility weights for
health states from published cost-utility analy-
ses 1976–2001. (Total = 2150; nine utility
weights gave only ranges and are therefore not
included in this figure).
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areas, there was considerable variability in the health
state descriptions (i.e., the disease severity, treatment
characteristics  and  side-effect  descriptions)  resulting
in wide utility ranges. For example, stroke weights
ranged from −0.02 to 0.90 depending on the severity
of the stroke in the health state description and the
characteristics of the population surveyed.
Compared with the weights published before 1998,
weights published from 1998 to 2001 were more fre-
quently elicited from members of the community (30%
up from 24%, P < 0.001), with fewer derived from
author or expert opinion in the absence of any other
formal methodology employed (19% vs. 33%,
P < 0.001). There was an increase in the number using
a generic instrument, and some notable changes in the
types of instruments used. For example, before 1997,
the EQ-5D was applied in 2% of cases; after 1997 it
rose to 12% (Table 1).
Discussion
We have updated a public-use catalog (http://
www.tuft-nemc.org/cearegistry) of health states and
corresponding utility weights, which now contains
2159 utility weights obtained from 25 years of pub-
lished CUAs. In the update period (1998–2001), we
were able to abstract appropriate information for
more than 90% of analyses, a comparable rate to that
found before 1998 [13]. In more than half of the
update articles, a previously published study was used
to estimate the weight. Because the majority of these
estimates were new to our catalog, only 91 health
states (4%) were excluded for referencing the same
original source as another health state in our catalog;
this may represent a trend to separately publish results
of utility elicitation before using these weights in a
formal CUA.
Despite the large number of utilities included, many
clinical areas are still poorly represented in our utility
catalog. High morbidity conditions such as muscu-
loskeletal diseases continue to have few utility esti-
mates available. Thus, it appears there is substantial
room for further research to expand our base of
catalogued utilities available to researchers and
decision-makers.
Table 1 Measurement technique and population source for











Generic tool 20.0 25.5 0.003
Rosser Index 6.8 0.4 <0.001
EQ-5D (EuroQol) 2.3 11.5 <0.001
Quality of Well-Being scale 5.7 4.4




Rating scale 10.0 8.3
Author/clinical judgment 32.5 18.8 <0.001
Source of utility weights
Community 23.5 30.3 <0.001
Patients 26.8 23.3
Clinician 35.8 21.0 <0.001
Author 25.1 18.7 <0.001
The total does not add up to 100% because some states did not clearly state the
measurement technique used, or the source of the quality of life weights, and some
states used multiple techniques or had multiple sources of estimates.
*P-value only shown if <0.05 (chi-square test).
Figure 3 Number of health state descriptions
and utility weights by disease category, elicited
from the community, using a generic instru-
ment, from published cost-utility analyses.
(Total = 409).
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Many of the health states in our catalog had wide
ranges of utilities reported. Past studies suggest that
the disparate utility estimates may result from differ-
ences in the health state descriptions or the popula-
tions from which the utilities were elicited [12–14,21–
23]. For example, published myocardial infarction
(MI) utilities are estimated at 0.58 and 0.88 in separate
studies. The lower utility (0.58) was elicited using the
EQ-5D in patients after peripheral vascular surgery, a
subset of which had a postoperative MI [24]. In con-
trast, the higher utility (0.88) was elicited using time
trade-off, in patients with a recent MI and a mildly
depressed ejection fraction but no clinical symptoms of
heart failure [25]. Subtle differences in the descriptions
of seemingly similar health state may also have led to
the wide variations found in the published utilities for
health states.
The wide utility ranges for the same health states
highlights the need for researchers to carefully consider
which utility estimates they ultimately use in their
analyses. Future studies would do well to use the util-
ities obtained from the most methodologically sound
studies, in the most comparable populations, and
using the most relevant health state descriptions.
Despite this choice of a “best-utility estimate,” for base
case analyses, researchers would do well to explore a
range of cataloged health state utilities in sensitivity
analyses. The utilities chosen for a health state range
may depend on the disease. For example in stroke with
such a wide range of utilities, it may be useful to
explore the range associated with the “best utility esti-
mate” rather than the full range from the catalog.
Indeed, perhaps the most important use of the catalog
may be the identification of a relevant range of utility
weights to include in sensitivity analyses.
There appears to be some improvement in the meth-
ods used to value health states over time. This trend
after publication of the Panel’s recommendations, sug-
gests that researchers may be making an effort to
adhere to the Panel’s methodological recommenda-
tions. Still, many studies do not adhere to recom-
mended practices and a large number do not make
their techniques explicit. Even in the 1998–2001 time
period, study authors did not clearly define the popu-
lation source for 12% of utility weights, and for 18%
they did not state the elicitation technique used. The
persistent of these variations is troubling. Likely con-
cerns about the comparability and credibility of anal-
yses will persist without further improvements and
standards in the field.
A number of study limitations warrant mention.
Our search strategy was limited to select key words
and the search was restricted to original CUAs.
Therefore, some well-designed utility elicitation stud-
ies may have been omitted. Second, our data abstrac-
tion accuracy was limited by the availability of
correct data in the original documents. If authors
failed to offer comprehensive descriptions of health
states or methods, this may be reflected in our data-
base; although we tried to obtain the necessary infor-
mation from other references or authors, we were
sometimes unsuccessful.
Handling of patient preferences is one of the most
challenging issues in cost-effectiveness analysis. The
challenge for the future will be to find reliable and
valid measurement techniques, and to use them con-
sistently across studies and over time. In the mean
time, researchers should be encouraged to present their
methodology in a clear and transparent way so that
analysts and decision-makers are aware of how the
utilities selected affect the cost per QALY ratios found.
It is our hope that posting of our catalog on the World
Wide Web will help ensure broad access for research-
ers to identify relevant utility weights for point esti-
mates and appropriate ranges for sensitivity analyses.
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